Iradimed Corp. (IRMD) announced on Friday that it anticipates its fourth-quarter preliminary unaudited revenue will grow between 10% and 11%, reaching an estimated range of $19.2 million to $19.4 million.
For the complete fiscal year, the company forecasts revenue to be approximately between $73.1 million and $73.3 million, reflecting an increase from $65.6 million reported in the previous year for 2024.
At present, Iradimed's stock is valued at $57.25, reflecting a decrease of 1.65% on the Nasdaq.
